## **Special Issue**

# Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis

## Message from the Guest Editor

Lung cancer is the most common cause of cancerrelated mortality worldwide. Although new therapeutic strategies are defined according to the molecular profile of the tissue, a high rate of these targeted therapies fail to cure the disease because of several biological and technological challenges, mainly the heterogeneity of the tumor. The purpose of this Special Issue, Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis, is to highlight: 1) the benefit of personalized medicine in the diagnosis, treatment, and prognosis of lung cancer patients; 2) the new assays that could achieve high sensitivity for early detection of minimal residual disease (MRD) in lung cancer patients; 3) the crucial role of liquid biopsies in personalized medicine in lung cancer; and 4) the spatial heterogeneity as well as temporal heterogeneity between the primary tumor and local or distant recurrences in the same patient. Finally, we also wish to present the rapid development of technology and drugs in this area of research.

## **Guest Editor**

Dr. Athina N. Markou

Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece

## Deadline for manuscript submissions

closed (31 March 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



## mdpi.com/si/95252

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

## Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

